
Spinal muscular atrophy patients have urged the Hong Kong government to expand subsidised medicine options for adults to increase their chances for a better quality of life, with some saying their condition deteriorated after growing up without affordable care.
Lui Man-lam, president of the Hong Kong Neuro-Muscular Disease Association, said at a press conference on Sunday that while oral medicine subsidies for those aged 25 or above were rolled out early this year, adult patients still lacked public funding for injection therapy to improve their condition.
“We are advocating equal subsidies for both treatment options – not out of preference but because of individual medical needs,” Lui said.
Advertisement
Spinal muscular atrophy is a hereditary neuromuscular disease in which motor neurons in the spinal cord and lower brainstem progressively deteriorate, weakening muscles and impairing movement, swallowing and breathing.
Hong Kong began to subsidise injection treatment for spinal muscular atrophy patients under the age of 18 in 2018, expanding it the next year to two more disease types via the Community Care Fund.
Advertisement
Oral medication for the disease was registered in 2021 and supplied to child patients. In late 2025, those over the age of 25 could register for it, with subsidies from the fund available from the first quarter of this year.


Russia’s Taliban Gamble is Not Paying Off
On state visits and foreign relations, Xi Jinping’s grip on power, Malaysia Indians, and other stories | Asia Sentinel Stories of the Week
Vietnam–Japan 2050: From Strategic Trust to a Shared Indo-Pacific Future